Filing for patents, especially for treatments in specialized areas like Netherton Syndrome, indicates Quoin Pharmaceuticals' commitment to innovation and securing its intellectual property. This move could protect the company's market position and attract investor interest due to the potential for exclusive rights to a novel treatment. The positive impact on QNRX's stock price in the short term is likely due to increased investor confidence in the company's research and development capabilities and the potential for future revenue from the patented product.